BIOMARKERS FOR DEMENTIA DIAGNOSIS

VolverGo back

Resultados 64 results. LastUpdate Updated on 30/11/2022 [13:30:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days



Page1/3 nextPage   results/page


ANTIBODIES RECOGNIZING TAU

Publication No.: US2022372118A1 24/11/2022

Applicant:

PROTHENA BIOSCIENCES LTD [IE]

PE_20190208_A1

Absstract of: US2022372118A1

The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

traducir

DETECTION OF ANTIBODIES AGAINST RAN PROTEINS FROM SERUM AND TISSUE LYSATES

Publication No.: US2022373559A1 24/11/2022

Applicant:

UNIV FLORIDA [US]

JP_2022548313_PA

Absstract of: US2022373559A1

Aspects of the disclosure relate to methods and compositions (e.g., kits) for detecting anti-repeat-associated non-ATG (RAN) protein antibodies in a subject (e.g., a subject that has been administered a therapeutic anti-RAN protein antibody or a vaccine against a disease or disorder associated with RAN protein expression, translation, and/or accumulation, for example amyotrophic lateral sclerosis (ALS) and/or frontotemporal dementia (FTD)). In some embodiments, methods described by the disclosure comprise detecting one or more anti-RAN protein antibodies in a biological sample obtained from a subject by an electrochemiluminescence-based immunoassay using one or more target di-amino acid repeat peptides. In some embodiments, the disclosure relates to kits comprising one or more di-amino acid repeat peptides and an electrochemiluminescence-based immunoassay plate and/or reagents.

traducir

SENSOR CHIP AND METHODS THEREOF

Publication No.: US2022373562A1 24/11/2022

Applicant:

NAT UNIV SINGAPORE [SG]

JP_2022519067_A

Absstract of: US2022373562A1

The present disclosure relates generally to a sensor chip and methods for the detection of an analyte. In particular, the disclosure relates to a sensor chip for detecting an analyte in a subject suffering from a neurodegenerative disease. The sensor chip comprises a conductive layer on a membrane support layer, wherein a plurality of apertures extend through the conductive layer and the membrane support layer and are arranged such that illumination of the conductive layer and/or the membrane support layer produces a surface plasmon resonance.

traducir

METHODS OF DETECTING NEUROLOGICAL DISORDERS VIA BINDING TO PHOSPHORYLATED TAU PROTEIN

Publication No.: US2022370642A1 24/11/2022

Applicant:

AMYDIS INC [US]

JP_2022548158_PA

Absstract of: US2022370642A1

Provided herein are methods and compositions for determining whether a patient suffers from a neurological disease or disorder is provided, comprising detecting the presence of a phosphorylated tau protein in a tissue of the patient, wherein the detecting comprises contacting the phosphorylated tau protein with a compound described herein.

traducir

Potency assay

Publication No.: AU2021261282A1 24/11/2022

Applicant:

LONGEVERON INC

WO_2021216580_A1

Absstract of: AU2021261282A1

A method for assessing the potency of MSCs to produce anti-inflammatory cytokines in response to a pro-inflammatory stimulus. The method comprises stimulating the MSCs with one or more proinflammatory cytokines, such as TNF-α, for a duration of time and then identifying and quantifying the production of anti-inflammatory cytokines. MSCs that produce potent levels of anti-inflammatory cytokines in response to TNF-α can be used in treatments for aging-related conditions, including aging frailty and Alzheimer's disease, and can also be used to treat corona virus infections. The method shows that TNF-α induced MSCs robustly secrete several anti-inflammatory cytokines, including IL-1 receptor antagonist (IL-1RA), IL-10, and granulocyte colony stimulating factor (G-CSF).

traducir

Compounds and methods targeting interleukin-34

Publication No.: AU2021264421A1 24/11/2022

Applicant:

LILLY CO ELI

US_2021363232_A1

Absstract of: AU2021264421A1

The present invention relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer's Disease or a tauopathy disease.

traducir

METHODS OF SCREENING FOR CONDENSATE-ASSOCIATED SPECIFICITY AND USES THEREOF

Publication No.: JP2022548695A 21/11/2022

Applicant:

デューポイントセラピューティクス,インコーポレイテッド

US_2022365093_PA

Absstract of: WO2021055644A1

Methods of identifying a compound, such as a test compound, and applications thereof are provided. For example, methods of identifying a compound that preferentially affects, increases, or decreases a level of association of a macromolecule with one or more target condensates or methods of identifying a compound that preferentially causes a macromolecule to associate or disassociate with one or more target condensates are provided. Additionally, methods of designing and/or identifying and/or making a compound, or portion thereof, with a desired characteristic are provided.

traducir

DIAGNOSIS OF FRONTOTEMPORAL DEMENTIA

Publication No.: US2022364175A1 17/11/2022

Applicant:

YEDA RES & DEV [IL]
UCL BUSINESS LTD [GB]

WO_2021130753_A1

Absstract of: US2022364175A1

A method of diagnosing Frontotemporal dementia (FTD) in a subject in need thereof is provided. The method comprising detecting a level of at least one micro RNA (miR) selected from the group consisting of hsa-miR-361-5p, hsa-miR-629-5p, hsa-miR-628-3p, hsa-miR-379-5p, hsa-miR-1-3p, hsa-miR-26a-5p, hsa-miR-125a-5p, hsa-miR-125b-5p, hsa-miR-142-5p and hsa-miR-340-5p in a biological sample of the subject, wherein when said level of said at least one micro RNA (miR) is higher than that in a control sample, it is indicative of FTD.

traducir

Methods for treating alzheimer's disease

Publication No.: AU2021249050A1 17/11/2022

Applicant:

JEFFERIES WILFRED
SINGH CHAAHAT

WO_2021195750_A1

Absstract of: AU2021249050A1

The present invention provides a method of treating or delaying the onset of Alzheimer's disease or other neurological diseases in a patient having or at risk of developing Alzheimer's disease or other neurological diseases comprising administering to the subject an effective amount of an anti-angiogenic agent. In particular, the present invention provides a method of treating and/or delaying the onset of Alzheimer's disease or other neurological diseases by inhibiting Angiopoietin-2 mediated Tie-2 angiogenic pathway comprising administering to the subject an effective amount of an inhibitor of the Angiopoietin-2 mediated Tie-2 angiogenic pathway.

traducir

METHODS OF SCREENING FOR CONDENSATE-ASSOCIATED SPECIFICITY AND USES THEREOF

Publication No.: US2022365093A1 17/11/2022

Applicant:

DEWPOINT THERAPEUTICS INC [US]

JP_2022548695_PA

Absstract of: US2022365093A1

Methods of identifying a compound, such as a test compound, and applications thereof are provided. For example, methods of identifying a compound that preferentially affects, increases, or decreases a level of association of a macromolecule with one or more target condensates or methods of identifying a compound that preferentially causes a macromolecule to associate or disassociate with one or more target condensates are provided. Additionally, methods of designing and/or identifying and/or making a compound, or portion thereof, with a desired characteristic are provided.

traducir

SYSTEM, ASSAY AND METHOD FOR PARTITIONING PROTEINS

Publication No.: US2022365096A1 17/11/2022

Applicant:

BRIGHAM & WOMENS HOSPITAL INC [US]

US_2021318321_A1

Absstract of: US2022365096A1

The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.

traducir

METHOD FOR DIAGNOSING AND TREATING SUBJECTS HAVING SINGLE NUCLEOTIDE POLYMORPHISMS IN CHROMOSOME 2, 2:107,510,000-107,540,000 LOCUS

Publication No.: WO2022238905A1 17/11/2022

Applicant:

NEURIM PHARMACEUTICALS 1991 LTD [IL]

US_2022364172_A1

Absstract of: WO2022238905A1

Methods and products for identifying individuals who are likely to respond in a positive (benefit) or negative (harm) manner to a pharmacological drug treatment intended for treating or preventing a neuropsychiatric disorder, neurodegeneration, sleep-wake cycles such including and not limited to Alzheimer's disease, schizophrenia, autism and attention disorders based on single nucleotide polymorphisms (SNP) chromosome 2, 2: 107,510,000-107,540,000 locus (as disclosed in the Genome Reference Consortium Human genome build 37 (GRCh37)).

traducir

METHOD FOR DIAGNOSING AND TREATING SUBJECTS HAVING SINGLE NUCLEOTIDE POLYMORPHISMS IN CHROMOSOME 2, 2:107,510,000-107,540,000 LOCUS

Publication No.: US2022364172A1 17/11/2022

Applicant:

NEURIM PHARMACEUTICALS 1991 LTD [IL]

Absstract of: US2022364172A1

Methods and products for identifying individuals who are likely to respond in a positive (benefit) or negative (harm) manner to a pharmacological drug treatment intended for treating or preventing a neuropsychiatric disorder, neurodegeneration, sleep-wake cycles such including and not limited to Alzheimer's disease, schizophrenia, autism and attention disorders based on single nucleotide polymorphisms (SNP) chromosome 2, 2:107,510,000-107,540,000 locus (as disclosed in the Genome Reference Consortium Human genome build 37 (GRCh37)).

traducir

TREATMENT OF ALZHEIMER'S DISEASE

Publication No.: EP4087654A1 16/11/2022

Applicant:

SELONTERRA INC [US]

CN_114938633_PA

Absstract of: WO2021142163A1

The present invention provides compositions and methods using certain GPR4-regulated genes and expression products thereof (namely YAP1, CTGF, CCND3, BDNF, VCL, ITGB3) for diagnosis, treatment and prevention of Alzheimer's disease and Mild Cognitive Impairment. The present invention also relates to a method of identifying therapeutic agents to treat and diagnose Alzheimer's disease or Mild Cognitive Impairment based on the differential expression of GPR4-regulated genes.

traducir

HCBI, MSBI, MSSI AND CMI SEQUENCES AS AN EARLY MARKER FOR THE FUTURE DEVELOPMENT OF CANCER AND DISEASES OF THE CNS AND AS A TARGET FOR THE TREATMENT AND PREVENTION OF THESE DISEASES

Publication No.: EP4089183A1 16/11/2022

Applicant:

DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS [DE]

ES_2916709_T3

Absstract of: EP4089183A1

Described are HCBI (Healthy Cattle Blood Isolate), MSBI (Multiple Sclerosis Brain Isolate), MSSI (Multiple Sclerosis Serum Isolate) and CMI (Cow Milk Isolate) nucleotide sequences as well as probes and primers comprising part of said nucleotide sequences and antibodies against polypeptides encoded by said nucleotide sequences. Said compounds are useful as early markers for the future development of cancer and diseases of the CNS (Multiple sclerosis MS, Prion-linked diseases, amyotrophic lateral sclerosis, transmissible spongiforme encephalitis, Parkinson's disease, Alzheimer disease) and should represent targets for treatment and prevention.

traducir

METHODS OF DETECTING NEUROLOGICAL DISORDERS VIA BINDING TO PHOSPHORYLATED TAU PROTEIN

Publication No.: JP2022548158A 16/11/2022

Applicant:

アミディス,インコーポレイテッド

US_2022370642_PA

Absstract of: WO2021055639A1

Provided herein are methods and compositions for determining whether a patient suffers from a neurological disease or disorder is provided, comprising detecting the presence of a phosphorylated tau protein in a tissue of the patient, wherein the detecting comprises contacting the phosphorylated tau protein with a compound described herein.

traducir

ANTIBODIES TO AMYLOID BETA

Publication No.: JP2022172166A 15/11/2022

Applicant:

ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア

US_2020172602_A1

Absstract of: WO2018014126A1

The disclosure pertains to antibodies that bind A-beta oligomers and methods of making and using said antibodies.

traducir

Omega-3 fatty acid and vitamin D levels to identify and attenuate cognitive aging in individuals

Publication No.: JP2022172152A 15/11/2022

Applicant:

ソシエテ・デ・プロデュイ・ネスレ・エス・アー

JP_2022166175_A

Absstract of: AU2017408873A1

A method for identifying pre-disposition to cognitive decline in a subject, the method comprising determining levels of: (a) omega-3 fatty acids, and vitamin D or a metabolite thereof; (b) omega-3 fatty acids, and homocysteine; (c) vitamin D or a metabolite thereof, and homocysteine; or (d) omega-3 fatty acids, vitamin D or a metabolite thereof, and homocysteine, independently in one or more samples obtained from the subject.

traducir

BIOMARKERS AND TREATMENTS OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT

Publication No.: JP2022547513A 14/11/2022

Applicant:

アクソンニューロサイエンスエスエー

CA_3150156_PA

Absstract of: WO2021048619A2

The disclosure provides immunogenic peptides, compositions, means, and methods for treating Alzheimer's disease or mild cognitive impairment. The disclosure turther provides means and methods for diagnosing patients, selecting patients for treatment, and/or evaluating the efficacy of treatment for Alzheimer's disease or mild cognitive impairment

traducir

CHIMERIC PROTEIN IN THE TREATMENT OF AMYLOIDOSIS

Publication No.: US2022356219A1 10/11/2022

Applicant:

CENTRE NAT RECH SCIENT [FR]
UNIV LIMOGES [FR]

US_2018298071_A1

Absstract of: US2022356219A1

The present invention relates to a chimeric protein comprising at least one human amyloid P component and at least one fragment of an Fc region of a human antibody, the human amyloid P component and the fragment of an Fc region with which it is associated being bound to each other by means of a hinge region.

traducir

BLOOD-BASED ASSAY FOR DIAGNOSING AND TREATING BASED ON SITE-SPECIFIC TAU PHOSPHORYLATION

Publication No.: JP2022547209A 10/11/2022

Applicant:

ワシントン・ユニバーシティ

BR_112022004326_A2

Absstract of: WO2021050733A1

The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues, using blood samples, to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.

traducir

TEST STRIP AND METHOD FOR DETECTING AMYLOID BETA IN URINE

Publication No.: US2022357345A1 10/11/2022

Applicant:

HUNAN QIANKANG TECH CO LTD [CN]

JP_2022539580_PA

Absstract of: US2022357345A1

A test strip for detecting Aβ in urine includes a polyvinyl chloride (PVC) bottom plate. The PVC bottom plate is laid with a sample pad, a conjugation pad, a chromatography pad, and an absorbent pad that are overlapped in sequence. The conjugation pad is coated with colloidal gold particles conjugated to a monoclonal antibody. The chromatography pad is provided with a test line on the side proximate to the conjugation pad, and is provided with a control line on the side proximate to the absorbent pad. The test line is coated with an Aβ-binding polymer. The control line is coated with a goat anti-mouse IgG polyclonal antibody. The method is suitable for the following: routine clinical pathological examination; general screening of a large number of people and self-screening of home end-users; assisting the early diagnosis and prejudgment of mild cognitive impairment (MCI) clinically.

traducir

Lymphocyte-Based Morphometric Test for Alzheimer's Disease

Publication No.: US2022357315A1 10/11/2022

Applicant:

NEURODIAGNOSTICS LLC [US]

KR_20190132466_A

Absstract of: US2022357315A1

This invention provides methods for diagnosing Alzheimer's disease in a symptomatic human subject, and for determining whether a human subject is predisposed to becoming afflicted with Alzheimer's disease. These methods employ the steps of (a) culturing a subject's lymphocytes with a suitable basement membrane matrix to permit the lymphocytes to aggregate; (b) measuring the resulting lymphocyte aggregation; and (c) based on such measurement, either diagnosing Alzheimer's disease or determining a predisposition to it, as appropriate.

traducir

PRODUCTION METHOD FOR CEREBRAL ORGANOID

Publication No.: US2022356443A1 10/11/2022

Applicant:

UNIV KEIO [JP]

CN_114026222_A

Absstract of: US2022356443A1

A production method for a cerebral organoid having amyloid plaques is provided, the method including a step (a) of forming, in the presence of a SMAD inhibitor, an embryoid body from a pluripotent stem cell having a mutation in an Alzheimer's disease-related gene; a step (b) of embedding the embryoid body after the step (a) in an extracellular matrix and three-dimensionally culturing the embedded embryoid body in the presence of a SMAD inhibitor and a glycogen synthase kinase 3β (GSK3β) inhibitor to form an organoid; and a step (c) of removing the organoid after the step (b) from the extracellular matrix and subjecting the removed organoid to stirring culture in a medium, where at least a part of the step (c) is carried out in the presence of leukemia inhibitory factor (LIF).

traducir

AMYLOID BETA OLIGOMER DETECTION METHOD, AMYLOID BETA OLIGOMER DETECTION DEVICE, AND AMYLOID BETA OLIGOMER DETECTION PROGRAM

Nº publicación: US2022357276A1 10/11/2022

Applicant:

HAMAMATSU PHOTONICS KK [JP]

US_2019056324_A1

Absstract of: US2022357276A1

The present invention relates to a method for detecting an amyloid β oligomer which includes a test sample and thioflavin T are brought into contact with each other, fluorescence of the thioflavin T is measured to obtain time-resolved fluorescence spectra, the time-resolved fluorescence spectrum of time period t1 to t2 and the time-resolved fluorescence spectrum of time period t3 to t4 are respectively normalized to obtain normalized spectra (t1 traducir

Page1/3 nextPage results/page

punteroimgGo back